Artrya (ASX:AYA): Coronary Imaging Software and Its 2026 US Commercial Rollout

Aditi Sarkar

03 November 2026 05:53 PM AEDT

Artrya (ASX:AYA): Coronary Imaging Software and Its 2026 US Commercial Rollout

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Artrya reported a five-year commercial agreement with Huntsville Hospital Health System in October 2026.
Its Salix Coronary Plaque technology was part of the 2026 US commercial activities.
The September-quarter activities report was released on 26 October 2026.
US commercial deployment and scan utilisation remain important operating measures.

Artrya Limited (ASX:AYA) develops software for analysing coronary computed tomography angiography images and supporting coronary artery disease assessment through its Salix platform. Its shares closed at AUD 3.09 on 3 November 2026. The company’s 2026 reporting provides the context for assessing its operations, finances and next disclosed milestones.

US Commercial Agreements and Salix

In October 2026, Artrya (ASX:AYA) announced a five-year commercial agreement with Huntsville Hospital Health System for its Salix software. Its September-quarter activities report also described increased utilisation of the Salix Coronary Plaque module after a pre-authorisation workflow was implemented at Tanner Health. A commercial contract and subsequent usage are different measures: signing an agreement does not, by itself, establish Recurring Revenue at a particular scale.

Salix includes coronary anatomy and plaque-analysis capabilities linked to coronary CT angiography. The company has explained that its commercial model combines subscriptions and contracted fees linked to imaging activity. Hospital reimbursement rates cited in presentations are not the same as revenue received by Artrya; the company receives contractual payments under its arrangements with customers.

FY26 Reporting and Product Development

Artrya (ASX:AYA) published FY26 financial results and an operational update in September 2026. The update outlined its US sales approach and the separate Salix Coronary Flow component, which was then described as being in the final validation stage with US regulatory clearance targeted by the end of 2026. A target is not an approval, and clearance of one software module does not establish clearance of another.

The September-quarter report places emphasis on expanding installed customer relationships and converting clinical use into paid activity. Product adoption depends on hospital workflows, imaging volumes, clinical integration and any applicable approvals. Financial reporting should distinguish cash consumed in commercial expansion from payments received under customer arrangements, because increased commercial activity can require substantial expenditure before it results in cash generation.

Operating Risks and Financial Context

For Artrya Limited (ASX:AYA), the most useful assessment separates Business activity from financial outcomes. The distinction between an announced milestone and a completed commercial or financial outcome is important. Management disclosures can describe objectives, progress and planned next steps, but reported results provide the evidence of what was achieved during a particular period. Comparing successive reporting periods on the same accounting or operational basis helps avoid misleading conclusions. Sector-wide conditions can influence a business without demonstrating that they caused a particular daily share-price movement.

What to Watch Next

Important areas for the next published updates include usage across contracted hospitals, module-specific regulatory outcomes, recurring customer receipts and cash expenditure during US expansion. Each may affect the interpretation of the company’s progress, but none should be treated as a forecast of profitability, trial success or share-price performance. The timing of disclosures also matters because the information available at 3 November 2026 may not cover every development later in the financial year.

Key Insights

Artrya Limited (ASX:AYA) has reported developments during 2026 that relate to its operating model, financial resources and management priorities. Its latest disclosed measures need to be interpreted on their stated reporting basis. The next company updates may clarify the pace of activity, associated costs and the extent to which operational progress translates into recognised revenue, clinical evidence or available cash, as relevant to the business.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.